IL-28B/IFN-lambda 3 Antibody (244710)

Recombinant Mouse IL‑28B/IFN‑ lambda 3 (Catalog # 1789-ML) reduces the Encephalo­myocarditis Virus (EMCV)-induced cytopathy in the HepG2 human hepatocellular carcinoma cell line in a dose-dependent manner (orange line). Inhibition of EMCV activity elicited by Recom­-binant Mouse IL‑28B/IFN‑ lambda 3 (400 ng/mL) is neutralized (green line) by increasing concentrations of Rat Anti‑Mouse IL‑28B/IFN‑ lambda 3 Monoclonal Antibody (Cata­log # MAB1789). The ND50 is typically 1.5-6.0 µg/mL.

• Reactivity: Mu
• Applications: WB, B/N
• Clone: 244710
• Clonality: Monoclonal
• Host: Rat
• Conjugate: Unconjugated
• Concentration: LYOPH

IL-28B/IFN-lambda 3 Antibody (244710) Summary

• Immunogen: E. coli-derived recombinant mouse IL‑28B/IFN‑ lambda 3
  Asp20-Val193
  Accession # Q8CGK6
• Specificity: Detects mouse IL‑28B/IFN‑ lambda 3 in direct ELISAs and Western blots. In Western blots, approximately 25% cross-reactivity with recombinant mouse (rm) IL-28A/IFN-gamma 2 and no cross-reactivity with recombinant human (rh) IL-28A or rhIL-29 is observed. This antibody neutralizes 100% of the bioactivity of rmIL-28A/IFN-gamma 2.
• Source: N/A
• Isotype: IgG2b
• Clonality: Monoclonal
• Host: Rat
• Gene: Ifnl3
• Purity Statement: Protein A or G purified from hybridoma culture supernatant
• Endotoxin Note: <0.10 EU per 1 μg of the antibody by the LAL method.

Applications/Dilutions

• Dilutions:
  • Neutralization 1.5-6.0 ug/mL
  • Western Blot 1 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Concentration: LYOPH
• Reconstitution Instructions: Reconstitute at 0.5 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for IL-28B/IFN-lambda 3 Antibody (244710)

• interleukin-28B
• IFN-lambda 3
• IL28B
• IL-28B
• IL28C
• interferon, lambda 3

Background

Human IL-28A, IL-28B, and IL-29, also named interferon-lambda 2 (IFN-lambda 2), IFN-lambda 3, and IFN-lambda 1, respectively, are class II cytokine receptor ligands that are distantly related to members of the IL-10 family (11‑13% amino acid (aa) sequence identity) and the type I IFN family (15‑19% aa sequence identity) (1‑3). The genes encoding these three cytokines are localized to chromosome 19 and each is composed of multiple exons. The exon organization of these genes is also found in the IL-10 family genes but is distinct from the type I IFNs, which are encoded within a single exon. The expression of IL-28A, B, and IL-29 is induced by virus infection or double‑stranded RNA. All three cytokines exert bioactivities that overlap those of type I IFNs, including antiviral activity and up‑regulation of MHC class I antigen expression. The three proteins signal through the same heterodimeric receptor complex that is composed of the IL-10 receptor beta (IL-10 R beta ) and a novel IL-28 receptor  alpha (IL-28 R alpha , also known as IFN-lambda R1). Ligand binding to the receptor complex induces Jak kinase activation and STAT1 and STAT2 tyrosine phosphorylation. The phosphorylated STAT1 and STAT2 complex with IFN-regulatory factor 9 (IRF-9) to form the IFN-stimulated regulatory factor 3 (ISGF-3) transcription factor complex that is translocated to the nucleus. ISGF-3 binds to the IFN-stimulated response element (ISRE) present in the regulatory regions of the target genes. Mouse IL-28B cDNA encodes a 193 amino acid residue precursor protein with a putative 15 aa signal peptide. It shares 61%, 62% and 52% aa sequence identity with human IL-28A, human IL-28B and human IL-29, respectively.

1. Vilcek, J. (2003) Nature Immunol. 4:8.
2. Sheppard, P. et al. (2003) Nature Immunol. 4:63.
3. Kotenko, S.V. et al. (2003) Nature Immunol. 4:69.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for IL-28B/IFN-lambda 3 Antibody (MAB1789)(3)

Publications using MAB1789

• D Cheng, H Wang, H Cheng, H Zhang, G Dong, F Yan, Z Ning, C Wang, L Wei, X Zhang, J Zhang, H Xiong IL-28B reprograms tumor-associated macrophages to promote anti-tumor effects in colon cancer International immunopharmacology, 2022-05-04;109(0):108799. 2022-05-04 [PMID: 35525232] (Neutralization, Mouse)
• Sujin An, Yung Jin Jeon, Ara Jo, Hyun Jung Lim, Young Eun Han, Sung Woo Cho et al. Initial Influenza Virus Replication Can Be Limited in Allergic Asthma Through Rapid Induction of Type III Interferons in Respiratory Epithelium Frontiers in Immunology 5/17/2018 [PMID: 29867963]
• Sujin An, Yung Jin Jeon, Ara Jo, Hyun Jung Lim, Young Eun Han, Sung Woo Cho et al. Initial Influenza Virus Replication Can Be Limited in Allergic Asthma Through Rapid Induction of Type III Interferons in Respiratory Epithelium Frontiers in Immunology 2018-05-17 [PMID: 29867963] (In vivo assay, Mouse)

Bioinformatics

• Gene Symbol: Ifnl3
• Uniprot:
  • Q8CGK6()